e purpose of this report is to describe an expanded suture and needle clinical evaluation program jointly designed by hospital representatives of Consorta, Inc. (Rolling Meadows, Illinois), a leading healthcare resource management and group purchasing organization, and United States Surgical/Davis & Geck Sutures (Division of United States Surgical, Norwalk, Connecticut). In this expanded evaluation program, 42 Consorta shareholder hospitals enrolled 1913 surgeons to participate in Phase II of this non-experimental observational study of the clinical performance of surgical needles and sutures. Performance characteristics of the sutures and needles produced by USS/DG that were evaluated in 25,545 surgical procedures included packaging/ease of opening, needle strength and sharpness, tissue drag, knot security, tensile strength, clinically acceptable determinations, and clinically unacceptable determinations.
I. INTRODUCTION
Consorta, Inc. (Rolling Meadows, Illinois), a leading healthcare resource management group purchasing organization, and United States Surgical/Davis & Geck Sutures (Division of United States Surgical, Norwalk, Connecticut), jointly with a clinician task force, designed a reproducible surgical evaluation program for needles and sutures in a large cooperative of healthcare systems. Because of the subjective nature of the more commonly used suture selection techniques, a nonexperimental observational study approach was designed to replace perception of performance characteristics with actual clinical experience. In a preliminary report involving 19 Consorta shareholder hospitals, we reported the preliminary part (Phase I) of a large nonexperimental observational study of the clinical performance of surgical needles and sutures.¹ Performance characteristics of the sutures and needles produced by USS/DG that were evaluated in 3407 surgical procedures included packaging/ ease of opening, needle strength and sharpness, tissue drag, knot security, tensile strength, clinically acceptable determinations, and clinically unacceptable determinations. In this preliminary study, the surgeons concluded that the needles and sutures were clinically acceptable in 98.1% of the evaluations. e general, cardiothoracic, and orthopedic surgeons who performed 73.8% of the product evaluations reported that the suture and needle products were clinically acceptable in 97.2% of the evaluations.
Armed with this favorable experience, we wanted to expand this observational study to an entirely new group of shareholder hospitals that had a larger number of participating hospitals (Phase I, 19 hospitals; Phase II, 42 hospitals). is more than doubling of hospital observational base dramatically increased the number of patients and performance evaluations. In our preliminary study involving 3407 patients, we recorded 9266 evaluations of needle and suture products. In the Phase II expanded program involving 42 hospitals, the number of patients (8939) as well as the number of evaluations (25,545) were more than twofold greater than the preliminary study. e purpose of this report is to provide a detailed review of this expanded comprehensive observational study.
II. MATERIALS AND METHODS
Consorta, Inc. is a healthcare resource management and group purchasing organization whose shareholders are Catholic-sponsored, nonprofi t health systems. As a cooperative, Consorta's shareholders share fully in the organizations performance, as well as receiving competitive prices through scale purchasing economies. Consorta, Inc., provides opportunity for improving hospital care by including its outcomes comparisons for wound closure, which provides benchmark data for performance improvement. eir data-driven contracting process facilitates administrative and surgeon participation in the selection of the optimal products for wound closure. Forty two of the shareholder hospitals participated in the study that involved 8939 surgical patients.
II.A. Suture and Needle Product Evaluation
e suture and needle product evaluation was divided into two distinct steps: pre-evaluation and evaluation. e overall objectives of this suture and needle evaluation was to establish clinical acceptance using an unbiased method, measuring the willingness of surgeons and staff to use suture and needle products from whatever supplier was awarded a Consorta, Inc., agreement, and to achieve the best competitive price for the suture and needle product. Consorta, Inc., and USS/DG Sutures prepared a manual that provided a clear understanding of their goals and objectives, as well as the evaluation process.
A.1. Pre-evaluation Process
As a fi rst step, the hospitals were asked to review and sign an evaluation plan outlining the supplier's and hospitals' responsibilities in creating an unbiased environment for the evaluation. Prior to the evaluation, an evaluation team consisting of the executive administrator, materials manager, operating room directors, nurse managers, and all surgeons was formed. A project leader from the team was identifi ed to coordinate all aspects of the evaluation process with the supplier  whose products were being evaluated and to meet daily with the supplier's team members. A nurse leadership seminar and a site visit to the supplier's manufacturing facilities was undertaken to ensure thorough education of key personnel on the products and on the quality assurance standards that the products must meet. In addition, the supplier had to designate a supplier evaluation team with representation determined by location and hospital requirements. e supplier team had to be onsite at each hospital for the 30-day evaluation period. e supplier had to provide onsite nursing and surgeon in-service training programs to insure proper communication and education on the process and products being evaluated. e supplier team and evaluation team developed a suture and needle evaluation form including the following minimum evaluation criteria: packaging/ease of opening, needle strength and sharpness, tissue drag, knot security, tensile strength, clinically acceptable determinations, and clinically unacceptable determinations.
e evaluation team developed plans to prohibit access to the representatives from incumbent suture product suppliers to the hospital site during the 30-day evaluation process. Competitive products were removed from the operating room area to assure adequate opportunity for a fair trial of the new product. At the end of the 30-day evaluation, the incumbent products replaced the inventory of new products provided by the supplier.
A.2. Evaluation Process
All surgeons and staff participated in the evaluation of the suture and needle products of USS/DG Sutures. If a surgeon chose not to participate, he/she would not have a role in the decision-making process. Uniform evaluation tools were provided to collect clinical feedback. All participants were asked to sign the evaluation forms after adequate experience with the products. A copy of the completed evaluation forms was available to both the project leader and the supplier on a daily basis. e surgeons' feedback on nonacceptable products was pursued immediately to determine clinical justifi cation as well as proposed solutions to meet the surgeon's needs. e core measure of the criteria on which the suture and needle products were evaluated was clinical acceptability. Feedback on the products' clinical acceptability was provided on the evaluation forms.
e evaluation results from all 42 hospitals were aggregated and summarized by Consorta, Inc., for each shareholder. e fi nal summary was reported to Consorta, Inc. Contracts and Programs, the Surgical Advisory Subcommittee, and the Suture Product Task Force.
II.B. Sutures
Important considerations in wound closure are the type of suture and its mechanical performance in vivo and in vitro. Measurements of the in vivo degradation of sutures separate them into two general classes. Sutures that undergo rapid degradation in tissues, losing their tensile strength within 60 days, are considered absorbable sutures. ose that maintain their tensile strength for longer than 60 days are nonabsorbable sutures. is terminology is somewhat misleading because even some nonabsorbable sutures (i.e., silk and nylon) lose some tensile strength during this 60-day interval. Postlethwait² measured the tensile strength of implanted nonabsorbable sutures during a period of 2 years. Silk lost approximately 50% of its tensile strength in 1 year and had no strength at the end of 2 years. Nylon lost approximately 25% of its original strength throughout the 2-year observation period. e silk fi bers are treated to remove the naturally occurring sericin gum, and braided sutures are available coated uniformly with a special wax mixture to reduce capillarity and to increase surface lubricity, which enhances handling characteristics, ease of passage through tissue, and knot run-down properties. * sutures are available colored black with Logwood extract.
Metallic sutures are derived from stainless steel. Modern chemistry has developed a variety of synthetic fi bers ranging from polyamides (nylon), to polyesters (Dacron), to polyolefi ns (polyethylene, polypropylene), to polytetrafl uoroethylene, to polybutester.
Polypropylene is a linear hydrocarbon polymer that consists of a strand of polypropylene, a synthetic linear polyolefi n. All polypropylenes begin with a base resin and then go through the following steps: extrusion, drawing, relaxation, and annealing. Each step in the process infl uences the ultimate biomechanical performance of the suture. Biomechanical studies demonstrate that the manufacturing process (i.e., annealing, relaxation) can dramatically infl uence the surface characteristics without altering its strength. Changes in the surface characteristics can facilitate knot construction of the suture. Polypropylene sutures (*, *) that have a low coeffi cient of friction will facilitate knot rundown and suture passage through the tissue. A new polypropylene suture (*) has been developed that has increased resistance to fraying during knot rundown, especially with smaller diameter sutures. Polypropylene sutures are extremely inert in tissue and have been found to retain tensile strength in tissues for as long as 2 years. Polypropylene sutures are widely used in plastic, cardiovascular, general, and orthopedic surgery. ey exhibit a lower drag coeffi cient in tissue than nylon sutures, making them ideal for use in continuous suture closure. * and * are monofi lament sutures composed of the long-chain polyamide polymers Nylon 6 and Nylon 6.6. While they have a high tensile strength and low tissue reactivity, they degrade in vivo at a rate of about 12.5% per year by hydrolysis.
e pliability characteristics of these sutures permit good handling. Because nylon sutures are more pliable and easier to handle than polypropylene sutures, they are favored for the construction of interrupted percutaneous suture closures. However, polypropylene sutures encounter lower drag forces in tissue on sutures, accounting for their frequent use in continuous dermal and percutaneous suture closure. Nylon sutures are also available in a braided construction (*). ese braided nylon sutures are relatively inert in tissue and possess the same handling and knot construction characteristics as the natural fi ber silk sutures (*).
Polyester sutures (*, -*) are composed of fi bers of polyethylene terephthalate, a synthetic linear polyester derived from the reaction of a glycol and a dibasic acid. Polyester sutures were the fi rst synthetic braided suture material shown to last indefi nitely in tissues. eir acceptance in surgery was initially limited because the suture had a high coeffi cient of friction that interfered with passage through tissue and with the construction of a knot. When the sutures were coated with a lubricant, they gained wide acceptance in surgery. is coating markedly reduced the suture's coeffi cient of friction, thereby facilitating knot construction and passage through tissue. e -* polyester sutures are coated with silicone, while the surface lubricant for * is polybutylene adipate. Because some surgeons prefer to tie sutures with a high coeffi cient of friction, the -* sutures are also available without a surface coating. In this observational study, only the coated -* sutures were used. e polybutester suture (*) is a block copolymer that contains butylene terephthalate and polytetra methylene ether glycol. e polybutester suture has unique performance characteristics that may be advantageous for wound closure.³ is monofi lament synthetic nonabsorbable suture exhibits distinct diff erences in elongation compared with other sutures. With the polybutester suture, low forces yield signifi cantly greater elongation than seen in the other sutures. In addition, its elasticity is superior to the other sutures, allowing the suture to return to its original length once the load is removed.
e clinical performance of polybutester suture has been enhanced by coating its surface with a unique absorbable polymer (*).⁴ e coating is a polytribolate polymer that is composed of three compounds: gylcolide, ε-caprolactone, and poloxamer 188. Coating the poly butester suture markedly reduces its drag force in musculoaponeurotic, colonic, and vascular tissue.
e nonabsorbable sutures also may be characterized by their physical confi gurations. Sutures constructed from one fi lament are called monofi lament sutures (nylon, propropylene, polybutester, polytetrafl uoroethylene, and stainless steel). Sutures containing multiple fi bers are called multifi lament sutures (nylon, polyester, stainless steel, and silk.) Only nylon and stainless steel sutures are available both as a monofi lament and as a multifi lament suture. Monofi lament stainless steel (*) is manufactured as diff erent diameter single strands of stainless steel. Multifi lament stainless steel sutures (*) are formed by winding one fi lament around another, forming a twisted suture. Long, continuous strands of stainless steel are twisted together to form diff erent gauge sutures. Intertwining three or more fi laments forms the other multifi lament sutures. Several very fi ne silk fi bers are twisted together to form yarns, which are then braided. e number of silk fi bers used regulates the suture gauge. A large gauge suture can be made with braids of synthetic fi laments by either increasing the number of fi laments or enhancing the size of the fi laments.
B.2. Absorbable Sutures
e absorbable sutures of USS/DG Sutures are made from either collagen or synthetic polymers.
e collagen sutures are derived from the submucosal layer of ovine small intestine or the serosal layer of bovine small intestine (gut). is collagenous tissue is treated with an aldehyde solution, which crosslinks and strengthens the suture and makes it more resistant to enzymatic degradation. Suture materials treated in this way are called plain gut ( ). If the suture is also treated with chromium trioxide, it becomes chromic gut ( ), which is more highly crosslinked than plain gut and more resistant to absorption. When this treatment of collagen sutures is limited, the result is a special form of chromic gut ( ) that is more susceptible to tissue absorption. e plain gut and chromic gut sutures are composed of several plies that have been twisted slightly, machine ground, and polished, yielding a relatively smooth surface that is monofi lament-like in appearance. Salthouse and colleagues⁵ demonstrated that the mechanism by which gut reabsorbs is the result of sequential attacks by lysosomal enzymes. In most locations, this degradation is started by acid phosphatase, with leucine aminopeptidase playing a more important role later in the absorption period. Collagenase is also thought to contribute to the enzymatic degradation of these collagen sutures.
e type of gut being used determines the rate of absorption of surgical gut.   is rapidly absorbed. Its tensile strength is maintained for only 7-10 days post-implantation, and absorption is complete within 70 days.    has had a limited exposure to chromium trioxide to accelerate tensile strength loss and absorption. is fast-absorbing surgical gut is used primarily for ophthalmic and cuticular applications where sutures are required for only 5-7 days. e tensile strength of mild chromic gut may be retained for 10-14 days. Natural fi ber absorbable sutures have several distinct disadvantages. Fırst, these natural fi ber absorbable sutures have a tendency to fray during knot construction. Second, there is considerably more variability in their retention of tensile strength than is found with the synthetic absorbable sutures. A search for a synthetic substitute for collagen sutures began in the 1960s. Soon procedures were perfected for the synthesis of high molecular weight polyglycolic acid, which led to the development of the polyglycolic acid sutures (*, *).⁶ ese sutures are produced from the homopolymer, polyglycolic acid. Because of the inherent rigidity of this homopolymer, monofi lament sutures produced from polyglycolic acid sutures are too stiff for surgical use. is homopolymer can be used as a monofi lament suture only in the fi nest size. Consequently, this high molecular weight homopolymer is extruded into thin fi laments and braided.⁶ e thin fi laments of * are coated with *, a copolymer of glycolide and epsilon-caprolactone, to reduce the coeffi cient of friction encountered in knot construction. * is an uncoated braided suture.
e polyglycolic acid sutures (*, *) A monofi lament synthetic absorbable suture (*) has been developed using trimethylene carbonate.⁸ Glycolide trimethylene carbonate is a linear copolymer made by reacting trimethylene carbonate and glycolide with diethylene glycol as an initiator and stannous chloride dihydrate as the catalyst. e strength of the * suture is maintained in vivo much longer than that of the braided synthetic absorbable suture. is monofi lament suture retained approximately 50% of its breaking strength after implantation for 28 days, and still retained 25% of its original strength at 42 days. In contrast, braided absorbable sutures retained only 1-5% of their strength at 28 days.⁸ Absorption of the trimethylene carbonate suture is minimal until about the 60th day postimplantation and essentially complete within 6 months.
Another innovation in the development of monofi lament synthetic absorbable sutures has been the production of Glycomer 631, a terpolymer composed of glycolide (60%), trimethylene carbonate (26%), and dioxanone (14%) (*). e * has many distinct advantages over the braided synthetic absorbable sutures.⁹ Fırst, this monofi lament suture is signifi cantly stronger than the braided synthetic absorbable suture over 4 weeks of implantation. It maintains approximately 75% of its USP tensile strength at 2 weeks and 40% at 3 weeks postimplant. Absorption is complete between 90 and 110 days. In addition, this monofi lament suture potentiates less bacterial infection than does the braided suture. e handling characteristic of this monofi lament suture is superior to that of the braided suture because it encounters lower drag forces in tissue than does the braided suture.
e latest innovation in the development of monofi lament absorbable sutures has been the rapidly absorbing * suture. * monofi lament synthetic absorbable sutures are prepared from * 6211 synthetic polyester, which is composed of glycolide, caprolactone, trimethylene carbonate, and lactide. Implantation studies in animals indicate that * suture retains a minimum of 50-60% USP knot strength at 5 days post implantation and a minimum of 20-30% of knot strength at 10 days postimplantation. All of its tensile strength is essentially lost by 21 days postimplantation.
e direct correlation of molecular weight and breaking strength of the synthetic absorbable sutures with both in vivo and in vitro incubation implies a similar mechanism of degradation. Because in vitro incubation provides only a buff ered aqueous environment, the chemical degradation of these sutures appears to be by nonenzymatic hydrolysis of the ester bonds. Hydrolysis would be expected to proceed until small, soluble products are formed, then dissolved, and removed from the implant site. In contrast, the gut or collagen suture, being a proteinaceous  substance, is degraded primarily by the action of proteolytic enzymes.
A distinction must be made between the rate of absorption and the rate of tensile strength loss of the suture material. e terms rate of absorption and rate of tensile strength loss are not interchangeable. Although the rate of absorption is of some importance with regard to late suture complications, such as sinus tracts and granulomas, the rate of tensile strength loss is of much greater importance to the surgeon, considering the primary function of the suture, which is maintaining tissue approximation during healing.
When considering an absorbable suture's tensile strength in vivo, we recommend that the manufacturer provide specifi c measurements of its holding capacity, rather than the percentage retained of its initial tensile strength. e USP has set tensile strength standards for synthetic absorbable suture material. If the manufacturers were to use these standards to describe maintenance of tensile strength, the surgeon would have a valid clinical perspective to judge suture performance. Some manufacturers persist in reporting maintenance of the tensile strength of their suture in tissue by referring only to the percentage retained of its initial tensile strength, making comparisons among sutures diffi cult. e need to use USP standards in reporting is particularly important when there are marked diff erences in the initial tensile strengths of the synthetic sutures. For example, the initial tensile strength of Glycomer™ 631 (*) is 43% stronger than that of polydioxanone. However, at 2 weeks, the ™ suture is approximately 30% stronger.
II.C. Surgical Needles
Surgical needles of USS/DG Sutures are produced from stainless steel alloys, which have excellent resistance to corrosion.¹⁰ All true stainless steels contain a minimum of about 12% chromium, which allows a thin, protective surface layer of chromium oxide to form when the steel is exposed to oxygen. Since their development during the early 1960s, high nickel maraging stainless steels have found extensive use in structural materials in many applications requiring a combination of high strength and toughness. e basic principle of maraging consists of strengthening FeNi martensitic matrices by the precipitation of fi ne intermetallic phases, such as Ni 3 Ti. ese precipitates are so small that they are only evident on transmission electron microscopy. ey strengthen the metal by preventing the planes of atoms in the stainless steel from sliding over each other. A high nickel maraging stainless steel, such as S45500, is composed of 7.5-9.5% nickel, 0.8-1.4% titanium, and 11-12.5% chromium. In contrast, S42000 stainless steel is composed of 12-14% chromium without nickel or titanium. Scientists have successfully used the concept of high nickel maraging stainless steels (S45500) to develop stainless steel wires with superior strength and ductility for use as surgical needles. Surgical needles made of a high nickel maraging stainless steel have a greater resistance to bending and breakage than do stainless steels without nickel.
A new high-nickel stainless steel, *, has been used recently to manufacture surgical needles.¹¹ Biomechanical performance studies of cutting edge needles made of S45500 stainless steel alloy and * stainless steel demonstrated that needles made of  * had superior performance characteristics over those made of S45500. e * needles had considerably greater resistance to bending than the needle produced from the S45500 alloy. In addition, * stainless steel had an almost twofold greater resistance to fracture than did the S45500 stainless steel alloy.
C.1. Components of the Needle
Every surgical needle has three basic components: swage, body, and point.
Swage. A needle's swage is the site of attachment of the suture. Since 1914, an eyeless needle in which the suture was attached to a drilled hole in the needle has been used. e swaging process provides a smooth juncture between the needle and suture; needles produced by this swaging process thereby created smaller holes in tissue than did threaded eye needles. However, this swaging process was only pos- sible for larger diameter needles (>0.36 mm) because the mechanical drill could not reliably cut uniform holes in the ends of small needles. Consequently, a forming tool was used to create a channel in one half of the diameter of smaller-diameter needles with an underlying receptacle for the attachment of the suture. However, the linear splits in the walls of these smaller diameter needles increased the drag force encountered by tissues during needle passage. With the advent of the laser (yttrium-aluminum-garnet [YAG] laser), uniform holes are reliably produced in the ends of small needles, resulting in a smooth swage that encounters lower drag forces than with channel needles.¹² ese low drag forces caused by laser-drilled needles are associated with minimal mechanical trauma to tissues. e laser-drilled needles have other unique advantages over the channel needles related to the length of the swage ends. e length of the channel in channel swage needles is four times longer than that of the laser-drilled hole. Because swages are more susceptible than the body of the needle to bending and breakage by the needle holder jaws, surgeons are warned to grasp the needle with the needle holder at a site beyond the swage. In the case of 18-mm-long needles with laser-drilled and channel swages, the depths of the laser-drilled holes and channel swages are 1.5 mm and 6.0 mm, respectively. e laser-drilled needle can be held by the needle holder jaws 3 mm from the needle end, whereas the channel swage needle is grasped 7.5 mm from the needle end. By grasping the needle close to its end, the surgeon can more easily manipulate the passage of the needle through tissue. is benefi t of laser-drilled needles is accomplished without altering the needle suture attachment strength. ese distinct advantages of swages produced by lasers indicate that they should eventually replace all channel swage needles. e needle is attached to the suture by uniformly compressing the walls of the swage against the suture, creating a strong attachment force that prevents the surgeon from detaching the suture from the needle without exerting considerable force on the swage. is suture attachment force is so great that separation of the needle from the suture is accomplished more easily by cutting the suture rather than by applying suffi cient force to the suture to separate it from the swage. A special swage has been created by using lower compression forces around the circumference of the swage than conventionally used, allowing the surgeon to detach the suture from the needle using relatively low detachment forces, making it unnecessary to cut the suture. e swage requiring lower uniform forces to detach its suture has a variety of names, pop-off control release being one of them. It was originally developed for abdominal wound closure, bolus dressings for skin grafts, and hysterectomies in which large numbers of interrupted sutures are used.
Body.
e body of the needle is the portion grasped by the needle holder. e security with which needle holder jaws grasp the needle is infl uenced by the presence of teeth in the needle holder jaws, the ratchet setting of the needle holder handle, and the shape of the cross-sectional area of the needle body. Although the shape of the cross-sectional area of the body has a signifi cant eff ect on needle holding security, the presence of teeth in the needle holder jaws and the ratchet setting of the needle holder handle are much greater determinants of needle holding security than is the needle body shape.¹³ e shape of the cross-sectional area and the geometric confi guration of the length of the needle can categorize the geometry of the needle body. e shape of its cross-sectional area will infl uence the security with which the needle holder jaws grasp the needle, as well as its resistance to bending. e cross-sectional areas of the bodies of diff erent needles can be circular, triangular, rectangular, and trapezoidal. Needles with rectangular cross-sectional areas are created by fl attening either the sides or the top and bottom of the circular wire.
When the top and bottom portions of the needle body are fl attened, the long axis of its rectangular cross-sectional area will gain intimate contact with the faces of the needle holder jaw. is position of the needle body between the needle holder jaws is similar to that of the needle body with a trapezoidal shape. In both cases, the needle-holding security against twisting and rotation is greater than with any other needle body (side fl attening rectangular shape, triangular, and circular). is benefi t of enhanced needle holding security must be weighed against an associated reduced resistance to bending compared to that of the other needle bodies. Because we can increase the needle holding security of all needles by advancing the ratchet setting of the needle holder, we prefer side-fl attened needle bodies because they exhibit greater resistance to bending than any other needle body.
e geometry of the length of the needle will have considerable infl uence on the surgeon's use of a surgical needle. e curvature of the needle is described in degrees of the subtended arc. e radius of the needle is the distance from the center of the needle to the body of the needle, if the curvature of the needle was continued to make a full circle. e curvature of the needle with one radius of curvature may vary from 90° (¼), to 135° (⅜), to 180° (½), to 225° (⅝). A compound curved needle has two distinct radii of curvature. e type curvature of its tip extends 35° before it assumes a regular uniform curvature in the remaining portion of the needle body (100°).
e surgeon uses needles with a curvature of 135° to approximate divided edges of thin planar structures that are readily accessible (i.e., skin), requiring a limited arc of wrist rotation to pass the needle through the tissue. It is diffi cult to use the 135° needle in deep body cavities because the limited arc of wrist rotation in passing this needle is usually not suffi cient to expose the needle point, so that it will remain buried in the tissue and pose a challenge for the surgeon to retrieve. e 180° needle is ideally suited for use in deep body cavities because a limited arc of wrist rotation will successfully pass the entire needle through the tissue, allowing adequate exposure of the needle point for easy retrieval of the needle by the surgeon.
e surgeon uses needles with a 90° angle of curvature in microsurgery.
e compound curved needle has been primarily used to alter the geometry of 135° needles.¹⁴ e tight needle curvature at the point permits rapid, accurate needle passage at a selected depth and allows controlled exiting. Its design also off ers a mechanical advantage over the standard needle with one radius of curvature. Although originally designed for anterior segment ophthalmic surgery, the compound curved needle now has broader clinical applications that include vascular and microvascular surgery and dermal and skin closure.
In addition to its curvature and radius, a surgical needle can be characterized by three other measurements: chord length, needle diameter, and needle length. Chord length is the linear distance measured from the central point of the needle swage to the point of the needle. e needle diameter is the width of the original circular wire used in the manufacturing process for the production of the needle. Needle length is the arc length of the needle measured at the center of the wire's cross-section.
Point.
e point of the needle extends from the tip of the needle to the maximum cross section of the body. Each type of needle point is designed to penetrate specifi c types of tissue. In general, there are needles with cutting edges, taper points, or a combination of both. Cutting edge needles have at least two opposing edges that are designed to penetrate tough tissue. When cutting edge needles have three cutting edges, the position of the third cutting edge categorizes the needle as either a conventional cutting edge needle or a reverse cutting edge needle. Use of the conventional cutting edge needle leaves a hole that is susceptible to tissue cut-through. Because its third cutting edge is on the inside, concave, curvature of the needle, the inside cutting edge causes a linear cut that is perpendicular and close to the incision, against which the suture will exert a wound closure force that may ultimately cut through the tissue. In contrast, the third cutting edge of the reverse cutting edge needle is located on the outer convex curvature of the needle. When the reverse cutting edge needle cuts through skin, it leaves a wide wall of tissue, rather than an incision, against which the suture exerts its wound closure force. is wall of tissue resists suture cut-through.
Specifi cally designed cutting edge needles have been developed for anterior segment surgery in ophthalmology. ese needles received a modifi cation that converted the triangular geometry to a trapezoidal or spatulated confi guration by fl attening the outer convex surface. is fl attening process also produces a lateral widening of the needle body. In addition to ophthalmic surgery, these spatulated needles have been used successfully to repair lacerations of the nail matrix. Referred to as spatula needles, they are fl at on their concave and convex surfaces, with long sidecutting edges. e needle's side-cutting edges separate or split through the thin lamellar plane of corneal and scleral tissue with minimal damage.
e sharpness of cutting edge needles is increased by electrohoning, narrowing the needle point confi guration, narrowing the cutting edge angles, and providing a silicone coating. When the needle is electrohoned, its surface is polished while its edges are sharpened.
e taper point needle tapers to a sharp tip. It spreads the tissue without cutting it. e point geometry of this needle can be measured by its taper ratio, which is the length of the tapered portion of the needle divided by its diameter. e taper ratio of these needles varies from 12:1 to 8:1. ey are used in soft tissues that do not resist needle penetration, such as vessels, abdominal viscera, and fascia. ey are preferred when the surgeon wants to make the smallest hole possible in tissue without cutting.
All tapercut needles combine the unique features of taper point and cutting edge needles. e cutting edges of the tapercut needle extend only a very short distance from the needle tip and blend into a round taper body. In vascular surgery, tapercut needles are used frequently for the anastomosis of calcifi ed and fi brotic blood vessels to prosthetic grafts. Its cutting tip penetrates the calcifi ed portion of the artery without the cutting edges of the needle body tearing the friable vessel, thereby minimizing the risk of leakage around the needle puncture. Tapercut needles have also been advocated for closure of wounds in the oral mucosa. Its short cutting edges produce a tiny hole in the oral mucosa that is considerably smaller than that encountered with the cutting edge needles. e Penetrating Point needle is a * tapercut needle, used by cardiothoracic and vascular surgeons, that has a diamond-shaped point with a small, sharp cutting tip. Some surgeons have noted that the Penetrating Point * needle penetrates the calcifi ed tissue of vessels more easily than does the standard tapercut needle.
Extensive clinical investigations have demonstrated that blunt-tipped surgical needles dramatically reduce the risk of accidental injuries during surgery.¹⁵ e standard taper point needle tapers to a sharp point; in contrast, the blunt taper point needle has remarkably similar geometry to that of the taper point needle, except that its point has a blunt ending at the tip of the needle. e geometry of the blunt point needle diff ers from those of the taper point and blunt taper point needles. Instead of tapering to either a sharp or dull tip, it has no taper at all. Biomechanical performance studies in our laboratory demonstrated that either the taper blunt point or the blunt point needle dramatically enhance the resistance to needle penetration of either single or double gloves.¹⁵ e biomechanical performance of surgical needles and needle holders is determined by the following parameters: (1) needle sharpness, (2) needle resistance to bending, (3) needle ductility, and (4) needle holder clamping moment.¹⁶ A sharpness tester measures the force needed to pass a needle through a membrane that simulates the density of human tissue. Manufacturers measure needle resistance to bending in the laboratory by recording the force required to bend the needle 60° or 90° to determine the needle's ultimate bending moment. e more critical measurement to the surgeon is the needle's yield moment, the force required to irreversibly deform the needle. Ductility is a measurement of the needle's resistance to breakage. e needle holder clamping moment is a measure of the force exerted by the needle holder jaws on a curved surgical needle.
II.D. Packaging System For Surgical Needles and Sutures
Packages for surgical needles swaged to sutures have been designed and constructed by USS/DG Sutures to achieve several specifi c objectives.¹⁷ Fırst, the package and its contents must be susceptible to sterilization. Second, the package must aff ord convenient and sterile transfer of the surgical needles swaged to sutures to the sterile fi eld. e needle must be protected to prevent dulling of its cutting edges and point. Fınally, the suture must be kept as straight as possible until knot construction. USS/DG Suture developed a modern concept of packaging surgical needles swaged to sutures.

Each suture swaged to its needle is contained within at least two layers of packaging. ese two layers allow sterile transfer to the sterile fi eld. e "breather" or outer pouch is made of a laminate of Tyvek™ on one side and heat-sealed to plastic fi lm on the other. e exterior surfaces of this overwrap are not considered sterile. e inside surfaces of the overwrap and primary packet within it are sterile so long as the overwrap remains intact and undamaged.
e Tyvek™ backing is permeable to ethylene oxide, resulting in reliable gas sterilization of the inside of the overwrap as well as the inner packet containing the suture swaged to the needle. e outer wrap has two fl aps that are peeled apart, allowing transfer of the inner packet to the sterile fi eld. e outer wraps for the packages containing either absorbable or nonabsorbable sutures swaged to needles have identical dimensions and construction.
e braided sutures are packaged in a retainer of rigid fi lm having a spiral labyrinth specially designed for the delivery of a kink-free suture. e suture exits from this labyrinth in a manner that maintains the suture's straight, uniform confi guration. e braided absorbable suture is packaged in a sterile inner packet of hermetically sealed aluminum foil.
Because the physical and chemical properties of the monofi lament sutures are distinct from those of the braided sutures, a special inner packet has been designed for these sutures. e plastic memory for these monofi lament sutures is so great that the shape of the suture conforms to the shape of the packet. e monofi lament suture is wrapped around four fi xation pins in fi gure-eight-shaped loops. ese multiple loops are secured in medical grade paper boards. All braided and monofi lament sutures are swaged to needles, which are "parked" in foam to protect their delicate cutting edges and points.
III. RESULTS
Seven shareholder partners with their 42 hospitals participated in the Phase II suture and needle evaluation coordinated by Consorta Inc. of USS/DG Suture's products (Table 1 ). In this 30-day study, the evaluation involved surgery performed on 8939 patients, in which 25,545 suture and needle products were evaluated. e surgeons found that the suture and needle products were clinically acceptable in 98.1% of the evaluations. is high level of clinical acceptability of the surgical needle and suture products was encountered in all hospitals participating in the evaluation; the lowest rate of clinical product acceptability reported was 90.6%. (It is important to emphasize that only 39 patients were involved in this clinical evaluation; this hospital had the fewest patients of any hospital involved in this comprehensive study).
A wide range of surgical specialists agreed to participate in this study ( Table 2) . irteen surgical specialties, involving 1913 surgeons, were represented in the study. General surgeons performed more product evaluations (7438) than did any other specialty, followed by orthopedic surgeons (4279) and then cardiothoracic surgeons (3919). ese three specialties performed 61.2% of the product evaluations. e general, orthopedic, and cardiothoracic surgeons reported a remarkably high level and similar rate of suture and needle product acceptability of 98.8%, 98.0%, and 97.9%, respectively. Of all the surgical specialists, plastic surgeons gave the suture and needle products the lowest acceptability rating of 96.5% involving 947 product evaluations.
e suture and needle products received a nonacceptable rating in 485 evaluations (Table 2 .) e number of non acceptable ratings was greatest in obstetrics and gynecology (93 evaluations), followed by general surgery (87 evaluations), and then orthopedics (85 evaluations).
e performance of the surgical sutures was determined to be clinically acceptable in 25,060 evaluations (98.1%) ( Table 3 ). Nearly half (49.3%) of the evaluations of surgical sutures involved the * braided synthetic absorbable suture, which received a clinically acceptable rating in 98.2% of the evaluations. e second most frequently evaluated suture was *, which was determined to be clinically acceptable in 99.2% of the evaluations. e monofi lament nylon suture (*), followed by the monofi lament polypropylene suture (*), was the next most frequently used suture. e * was found to be clinically  (Table 4 ). e most frequently used needle assessed in this study was the taper point needle, which accounted for 14,368 evaluations, 63.4% of the total needle evaluations. is needle received a clinically acceptable rating in 98.0% of the evaluations. e next most frequently used needle was the  reverse cutting needle, which was evaluated in 5455 evaluations, 24.0% of the total needle evaluations. is  reverse cutting needle received a clinically acceptable rating in 98.2% of the evaluations.
e blunt point needles and the penetrating point needles had the lowest clinically acceptable ratings in the small number of patients in which they were used. e penetrating point needle was evaluated in only 15 trials and was found to be clinically acceptable in 86.7% of the trials. For the blunt point needles, its clinical acceptability rating was 78.6% in only 42 trials. 
IV. DISCUSSION
Consorta and USS/DG Sutures have designed and developed an intricate product evaluation plan that involves hospital administrators, surgeons, and supplier. Consorta, Inc., has made a major breakthrough in product selection by determining the clinical acceptability of the product in a hospital environment. It has determined the clinical acceptability of the products by using the surgeons' evaluations of the products in the operating room. In its expanded evaluation of sutures and needles made by USS/DG Sutures, Consorta, Inc., has evaluated the supplier's sutures and needles in 8939 patients involving 1913 surgeons from 13 specialties. In this expanded study involving 25,545 evaluations of suture and needle products made by USS/DG Sutures, the products of the supplier had an extremely high acceptability rating (98.1%.) While the study coordinated by Consorta, Inc., provides important guidelines for judging the clinical acceptability of suture and needle products in a hospital setting, this rigorous performance evaluation should provide the framework for evaluating the acceptability of a wide range of other biomaterials used in hospitals.
In any situation in which there was a low clinical acceptable rating, the lower rating was always related to a small number of clinical trials. For example, the hospital that had the lowest clinical acceptable rating of the needle and suture products (90.6%) involved only 64 out of the 25,545 total evaluations. Similarly, the suture that had the lowest rate of clinical acceptability was the * suture (83.3%), which was evaluated in only 12 trials. e surgical needles with the lowest clinical acceptability ratings, the blunt point needle (78.6%) and penetrating point needle (86.7%), were used in only 42 and 15 evaluations, respectively. Realizing the importance of an adequate number of clinical trials for any suture and needle evaluation, Consorta, Inc., undertook this Phase II expanded evaluation with a patient population that was more than twice that of the original report.¹ V. CONCLUSION e purpose of this report is to describe an expanded suture and needle evaluation program devised by Consorta, Inc., and USS/DG Sutures. Consorta, Inc., a leading healthcare resource and management group purchasing organization, coordinated this evaluation in its shareholder hospitals, reporting the results of their comprehensive performance evaluations of the suture and needle products made by USS/DG Sutures. A proprietary manual was prepared outlining the process by which the surgeons determined the performance of needles and sutures. e evaluation involved hospital executive administrators, materials managers, operating room directors, nurse managers and surgeons from 13 specialties.
is expanded evaluation involved 42 hospitals in which the supplier's suture and needle products were used in 8939 patients by 1913 surgeons. During this 30-day trial, there were 25,545 evaluations of the supplier's sutures and needles. e surgeons determined the performance of the needles and sutures to be acceptable in 98.1% of the evaluations. e surgeons, in their assessment of the individual suture and needle products, expressed a similarly extremely high level of satisfaction. e surgeons found that the needles were clinically acceptable in 97.9% of the evaluations, while the sutures were determined to be clinically acceptable in 98.1% of the evaluations. On the basis of their expanded evaluations of suture and needle products, Consorta, Inc., will be replicating their evaluation programs to access the clinical performance of other biomaterials commonly used in hospital settings.
